Fentiazac is a thiazole-based nonsteroidal anti-inflammatory drug (NSAID) developed for use in joint and muscular pain.[1] Like most other NSAIDs, it acts through inhibition of prostaglandin synthesis, via non-selective inhibition of both COX-1 and COX-2. First described in 1974, it was synthesized using the Hantzsch thiazole synthesis.[2]

Fentiazac was marketed under the trade-name Norvedan (among others), but its market status is currently unknown and assumed to be discontinued.[3]

See also

References

  1. ^ Lombardino JG (1985). Nonsteroidal antiinflammatory drugs. Vol. 247. New York: Wiley. p. 285. ISBN 978-0-471-89803-0.
  2. ^ Brown K, Cater DP, Cavalla JF, Green D, Newberry RA, Wilson AB (November 1974). "Nonsteroidal antiinflammatory agents. 1.2,4-Diphenylthiazole-5-acetic acid and related compounds". Journal of Medicinal Chemistry. 17 (11): 1177–1181. doi:10.1021/jm00257a010. PMID 4414839.
  3. ^ "FENTIAZAC". NCATS Inxight Drugs. National Center for Advancing Translational Sciences (NCATS); U.S. National Institutes of Health. Retrieved 2023-06-08.
Allikas: https://en.wikipedia.org/wiki/Fentiazac
No tags for this post.